Archives of Toxicology

, Volume 88, Issue 4, pp 901–911 | Cite as

Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients

  • Victor C. Lin
  • Chao-Yuan Huang
  • Yung-Chin Lee
  • Chia-Cheng Yu
  • Ta-Yuan Chang
  • Te-Ling Lu
  • Shu-Pin HuangEmail author
  • Bo-Ying BaoEmail author


Since the tumor protein p53 (TP53), a transcription factor, plays a crucial role in prostate cancer development and progression, we hypothesized that sequence variants in TP53 binding sites might affect clinical outcomes in patients with prostate cancer. We systematically evaluated 41 single nucleotide polymorphisms (SNPs) within genome-wide predicted TP53 binding sites in a cohort of 1,024 prostate cancer patients. The associations of these SNPs with prostate cancer characteristics and clinical outcomes after radical prostatectomy for localized disease and after androgen-deprivation therapy (ADT) for advanced disease were assessed by Kaplan–Meier analysis and Cox regression model. ARAP2 rs1444377 and TRPS1 rs722740 were associated with advanced stage prostate cancer. FRK rs171866 remained as a significant predictor for disease progression; DAB2 rs268091 and EXOC4 rs1149558 remained as significant predictors for prostate cancer-specific mortality (PCSM); and EXOC4 rs1149558 remained as a significant predictor for all-cause mortality after ADT in multivariate models that included clinicopathologic predictors. In addition, the numbers of protective genotypes at DAB2 rs268091 and EXOC4 rs1149558 showed a cumulative effect on PCSM (P for trend = 0.002). Our results suggested that SNPs within TP53 binding sites might be valuable biomarkers for prostate cancer outcome prediction.


Mortality Prognosis Prostate cancer Single nucleotide polymorphism (SNP) TP53 Transcription factor binding sites 



Single nucleotide polymorphism


Radical prostatectomy


Androgen-deprivation therapy


Prostate cancer-specific mortality


All-cause mortality


Prostate-specific antigen


Odds ratio

95 % CI

95 % confidence interval


Hazard ratio



This work was supported by grants from the National Science Council (NSC), Taiwan (NSC-98-2320-B-039-019-MY3, NSC-100-2314-B-039-009-MY3, and NSC-102-2628-B-039-005-MY3) and Kaohsiung Medical University Hospital (KMUH100-0R42). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We also thank Chao-Shih Chen for data analysis and the National Center for Genome Medicine, NSC, Taiwan, for technical support.

Conflict of interest

The authors declare no conflicts of interest.

Supplementary material

204_2014_1196_MOESM1_ESM.doc (232 kb)
Supplementary material 1 (DOC 231 kb)


  1. Amundson SA, Myers TG, Fornace AJ Jr (1998) Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17:3287–3299PubMedCrossRefGoogle Scholar
  2. Andriole GL, Crawford ED, Grubb RL 3rd et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319PubMedCentralPubMedCrossRefGoogle Scholar
  3. Bao BY, Lin VC, Huang SH et al (2010a) Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer. Ann Surg Oncol 17:1675–1681PubMedCrossRefGoogle Scholar
  4. Bao BY, Pao JB, Lin VC et al (2010b) Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta 411:1232–1237PubMedCrossRefGoogle Scholar
  5. Bao BY, Pao JB, Huang CN et al (2011) Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 17:928–936PubMedCrossRefGoogle Scholar
  6. Bao BY, Pao JB, Huang CN et al (2012) Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer 130:876–884PubMedCrossRefGoogle Scholar
  7. Brauer PM, Tyner AL (2009) RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle 8:2728–2732PubMedCentralPubMedCrossRefGoogle Scholar
  8. Bulyk ML (2003) Computational prediction of transcription-factor binding site locations. Genome Biol 5:201PubMedCentralPubMedCrossRefGoogle Scholar
  9. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO (1997) Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 57:4075–4081PubMedGoogle Scholar
  10. Chang CF, Pao JB, Yu CC et al (2013) Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Ann Surg Oncol 20:2446–2452PubMedCrossRefGoogle Scholar
  11. Dumont P, Leu JI, Della Pietra AC, George DL 3rd, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRefGoogle Scholar
  12. Ecke TH, Schlechte HH, Hubsch A, Lenk SV, Schiemenz K, Rudolph BD, Miller K (2007) TP53 mutation in prostate needle biopsies—comparison with patients follow-up. Anticancer Res 27:4143–4148PubMedGoogle Scholar
  13. Ferretti V, Poitras C, Bergeron D, Coulombe B, Robert F, Blanchette M (2007) PReMod: a database of genome-wide mammalian cis-regulatory module predictions. Nucl Acids Res 35:D122–D126PubMedCentralPubMedCrossRefGoogle Scholar
  14. Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61:365–369PubMedCrossRefGoogle Scholar
  15. Howell BW, Gertler FB, Cooper JA (1997) Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J 16:121–132PubMedCentralPubMedCrossRefGoogle Scholar
  16. Huang SP, Huang CY, Wang JS et al (2007) Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 13:6632–6638PubMedCrossRefGoogle Scholar
  17. Huang SP, Huang LC, Ting WC et al (2009) Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 18:3068–3074PubMedCrossRefGoogle Scholar
  18. Huang SP, Ting WC, Chen LM et al (2010) Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 17:312–322PubMedCrossRefGoogle Scholar
  19. Huang SP, Lan YH, Lu TL et al (2011) Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU Int 107:486–492PubMedCrossRefGoogle Scholar
  20. Huang CN, Huang SP, Pao JB et al (2012a) Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 23:707–713PubMedCrossRefGoogle Scholar
  21. Huang CN, Huang SP, Pao JB et al (2012b) Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med 271:499–509PubMedCrossRefGoogle Scholar
  22. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, Kent WJ (2004) The UCSC table browser data retrieval tool. Nucl Acids Res 32:D493–D496PubMedCentralPubMedCrossRefGoogle Scholar
  23. Li MS, Liu JL, Wu Y, Wang P, Teng H (2011) Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk. Genet Mol Res 10:2924–2933PubMedCrossRefGoogle Scholar
  24. Liu J, Yue P, Artym VV, Mueller SC, Guo W (2009) The role of the exocyst in matrix metalloproteinase secretion and actin dynamics during tumor cell invadopodia formation. Mol Biol Cell 20:3763–3771PubMedCentralPubMedCrossRefGoogle Scholar
  25. Mok SC, Chan WY, Wong KK et al (1998) DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16:2381–2387PubMedCrossRefGoogle Scholar
  26. Navone NM, Troncoso P, Pisters LL et al (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657–1669PubMedCrossRefGoogle Scholar
  27. Pao JB, Yang YP, Huang CN et al (2013) Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J Urol 31:281–287PubMedCrossRefGoogle Scholar
  28. Roche PJ, Hoare SA, Parker MG (1992) A consensus DNA-binding site for the androgen receptor. Mol Endocrinol 6:2229–2235PubMedGoogle Scholar
  29. Ross RW, Oh WK, Xie W et al (2008) Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26:842–847PubMedCrossRefGoogle Scholar
  30. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRefGoogle Scholar
  31. Stacey SN, Sulem P, Jonasdottir A et al (2011) A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 43:1098–1103PubMedCentralPubMedCrossRefGoogle Scholar
  32. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440–9445PubMedCentralPubMedCrossRefGoogle Scholar
  33. Sun T, Lee GS, Oh WK et al (2010) Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res 16:5244–5251PubMedCentralPubMedCrossRefGoogle Scholar
  34. Thorisson GA, Smith AV, Krishnan L, Stein LD (2005) The international HapMap project web site. Genome Res 15:1592–1593PubMedCentralPubMedCrossRefGoogle Scholar
  35. Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT (1998) Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 139:3542–3553PubMedGoogle Scholar
  36. Visakorpi T, Kallioniemi AH, Syvanen AC et al (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342–347PubMedGoogle Scholar
  37. Xu B, Mi YY, Min ZC et al (2010) p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urol Int 85:401–405PubMedCrossRefGoogle Scholar
  38. Yang TP, Beazley C, Montgomery SB et al (2010) Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 26:2474–2476PubMedCentralPubMedCrossRefGoogle Scholar
  39. Yoon HY, Miura K, Cuthbert EJ, Davis KK, Ahvazi B, Casanova JE, Randazzo PA (2006) ARAP2 effects on the actin cytoskeleton are dependent on Arf6-specific GTPase-activating-protein activity and binding to RhoA-GTP. J Cell Sci 119:4650–4666PubMedCrossRefGoogle Scholar
  40. Yu CC, Huang SP, Lee YC et al (2013a) Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS ONE 8:e54627PubMedCentralPubMedCrossRefGoogle Scholar
  41. Yu CC, Lin VC, Huang CY et al (2013b) Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 20(Suppl 3):492–499Google Scholar
  42. Zeitlinger J, Simon I, Harbison CT, Hannett NM, Volkert TL, Fink GR, Young RA (2003) Program-specific distribution of a transcription factor dependent on partner transcription factor and MAPK signaling. Cell 113:395–404PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Victor C. Lin
    • 1
    • 2
  • Chao-Yuan Huang
    • 3
  • Yung-Chin Lee
    • 4
    • 5
  • Chia-Cheng Yu
    • 6
    • 7
    • 8
  • Ta-Yuan Chang
    • 9
  • Te-Ling Lu
    • 10
  • Shu-Pin Huang
    • 4
    • 5
    Email author
  • Bo-Ying Bao
    • 10
    • 11
    Email author
  1. 1.Department of UrologyE-Da HospitalKaohsiungTaiwan
  2. 2.Department of NursingI-Shou UniversityKaohsiungTaiwan
  3. 3.Department of Urology, National Taiwan University Hospital, College of MedicineNational Taiwan UniversityTaipeiTaiwan
  4. 4.Department of UrologyKaohsiung Medical University HospitalKaohsiungTaiwan
  5. 5.Department of Urology, Faculty of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  6. 6.Division of Urology, Department of SurgeryKaohsiung Veterans General HospitalKaohsiungTaiwan
  7. 7.Department of Urology, School of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  8. 8.Department of PharmacyTajen UniversityPingtungTaiwan
  9. 9.Department of Occupational Safety and HealthChina Medical UniversityTaichungTaiwan
  10. 10.Department of PharmacyChina Medical UniversityTaichungTaiwan
  11. 11.Sex Hormone Research CenterChina Medical University HospitalTaichungTaiwan

Personalised recommendations